Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

Antiretroviral drugs may increase gay and bisexual men's susceptibility to syphilis

Antiretroviral drugs may increase gay and bisexual men's susceptibility to syphilis

The antiretroviral drugs used to treat HIV infection might inadvertently be boosting gay/bisexual men's susceptibility to the bacteria responsible for syphilis, Treponema pallidum, conclude researchers in the journal Sexually Transmitted Infections. [More]
Mylan announces U.S. launch of generic Concerta Tablets

Mylan announces U.S. launch of generic Concerta Tablets

Mylan N.V., today announced the U.S. launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, 18 mg, 27 mg, 36 mg and 54 mg, a generic version of Janssen's Concerta Tablets. [More]
Study highlights barriers to HIV care in sub-Saharan Africa

Study highlights barriers to HIV care in sub-Saharan Africa

Barriers to diagnosis and lack of access to modern medications have combined to place caregivers and HIV-positive patients in sub-Saharan Africa between a rock and a hard place. [More]
Blocking protein that initiates immune response against viral infections may help combat HIV

Blocking protein that initiates immune response against viral infections may help combat HIV

In findings they call counterintuitive, a team of UCLA-led researchers suggests that blocking a protein, which is crucial to initiating the immune response against viral infections, may actually help combat HIV. [More]
Heart attack risk for people with HIV nearly 50% higher than predicted

Heart attack risk for people with HIV nearly 50% higher than predicted

Current methods to predict the risk of heart attack and stroke vastly underestimate the risk in individuals with HIV, which is nearly double that of the general population, reports a new Northwestern Medicine study. [More]
Penn researchers pinpoint some effective HIV drugs in causing neuronal damage

Penn researchers pinpoint some effective HIV drugs in causing neuronal damage

Antiretroviral drugs have been life-changing therapies for HIV patients, but they can have significant side effects. [More]
ABIVAX reports preclinical data on first-in-class drug candidate for functional cure of HIV/AIDS patients

ABIVAX reports preclinical data on first-in-class drug candidate for functional cure of HIV/AIDS patients

ABIVAX an innovative biotechnology company targeting the immune system to eliminate viral disease, announced today that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/AIDS, during this week's HIV DART scientific conference in Los Cabos, Mexico. [More]
Project to help those living with HIV launched by Beckman Coulter

Project to help those living with HIV launched by Beckman Coulter

Beckman Coulter Life Sciences is launching an international HIV/AIDS award at the 2016 conference for the African Society for Laboratory Medicine (ASLM) being held in Cape Town, South Africa (December 3 to 8). [More]
Surveys reveal exceptional progress against HIV in Africa

Surveys reveal exceptional progress against HIV in Africa

National surveys in Zimbabwe, Malawi, and Zambia reveal exceptional progress against HIV, with decreasing rates of new infection, stable numbers of people living with HIV, and more than half of all those living with HIV showing viral suppression through use of antiretroviral medication. For those on antiretroviral medication, viral suppression is close to 90 percent. [More]
Liverpool-led research consortium aims to reduce mother-to-child transmission of HIV

Liverpool-led research consortium aims to reduce mother-to-child transmission of HIV

Researchers from the University of Liverpool's Institute of Translational Medicine have been awarded a grant of up to US$ 8.9 million (GBP £5.8m) to lead a multinational research consortium that aims to reduce mother-to-child transmission of HIV. [More]
FIRS calls on governments, health organizations to strengthen response to HIV on World AIDS Day

FIRS calls on governments, health organizations to strengthen response to HIV on World AIDS Day

In recognition of World AIDS Day, held annually on Dec. 1 each year since 1988, the Forum of International Respiratory Societies (FIRS) is calling on governments, health advocates and non-government organizations to strengthen their response to HIV/AIDS. In 2015 AIDS claimed 1.1 million lives. [More]

WHO releases new guidelines on self-testing to improve uptake of HIV diagnosis

In advance of World AIDS Day, the World Health Organization (WHO) has released new guidelines on HIV self-testing to improve access to and uptake of HIV diagnosis. [More]
NIH-supported first HIV vaccine efficacy study begins in South Africa

NIH-supported first HIV vaccine efficacy study begins in South Africa

The first HIV vaccine efficacy study to launch anywhere in seven years is now testing whether an experimental vaccine regimen safely prevents HIV infection among South African adults. [More]
Scientists develop new technology that sheds light on HIV infection

Scientists develop new technology that sheds light on HIV infection

A group of researchers at the Centre for Genomic Regulation and the Pompeu Fabra University in Barcelona, Spain, have developed a new technology that sheds light on the HIV infection and offers a first glance at the expression landscape of the HIV in the human genome. [More]
New antiretroviral treatments show potential to reduce chances of sexual transmission of HIV virus

New antiretroviral treatments show potential to reduce chances of sexual transmission of HIV virus

More than 2 million people got infected by human immunodeficiency virus (HIV) in 2015, being sexual transmission the main channel of infection. [More]
Scientists develop genetically engineered T cells with fusion inhibitor to disrupt HIV's harpoon

Scientists develop genetically engineered T cells with fusion inhibitor to disrupt HIV's harpoon

When HIV attacks a T cell, it attaches itself to the cell's surface and launches a "harpoon" to create an opening to enter and infect the cells. [More]
Broadly neutralizing antibody delays return of viral rebound in HIV-1 infected individuals

Broadly neutralizing antibody delays return of viral rebound in HIV-1 infected individuals

The administration of VRC01, a potent and broadly neutralizing HIV-specific antibody, is safe, is well-tolerated, generated high plasma concentrations and modestly delayed the return of HIV viral rebound in HIV-1 infected individuals after they stopped receiving antiretroviral therapy, according to a study published in the New England Journal of Medicine by researchers at the University of Alabama at Birmingham, the National Institutes of Health and the University of Pennsylvania Penn Center for AIDS Research. [More]
Research offers new insights into how immunotherapy could help treat or functionally cure HIV

Research offers new insights into how immunotherapy could help treat or functionally cure HIV

Immunotherapy has revolutionized treatment options in oncology, neurology, and many infectious diseases and now there is fresh hope that the same method could be used to treat or functionally cure HIV, according to two related studies from Perelman School of Medicine at the University of Pennsylvania, the University of Alabama at Birmingham, and the National Institutes of Health. [More]
Experimental vaccine/immune stimulant combination may lead to viral remission in HIV patients

Experimental vaccine/immune stimulant combination may lead to viral remission in HIV patients

A study led by researchers at Beth Israel Deaconess Medical Center, in collaboration with scientists at Walter Reed Army Institute of Research, Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson and Gilead Sciences, Inc., has demonstrated that combining an experimental vaccine with an innate immune stimulant may help lead to viral remission in people living with HIV. [More]
Investigational treatment combination improves virologic control in SIV-infected monkeys

Investigational treatment combination improves virologic control in SIV-infected monkeys

Researchers have found that an investigational treatment combination of a therapeutic vaccine and an immune-stimulator improves virologic control and delays viral rebound following the discontinuation of antiretroviral therapy (ART) in non-human primates infected with SIV, the simian form of HIV. [More]
Advertisement
Advertisement